BioLineRx Ltd. (BLRX) Given a $3.00 Price Target by Maxim Group Analysts

BioLineRx Ltd. (NASDAQ:BLRX) received a $3.00 price target from Maxim Group in a research report issued on Monday, July 10th. The firm presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price objective suggests a potential upside of 154.24% from the company’s previous close.

BLRX has been the topic of a number of other reports. HC Wainwright set a $4.00 target price on BioLineRx and gave the company a “buy” rating in a research note on Tuesday, April 18th. Zacks Investment Research lowered BioLineRx from a “buy” rating to a “hold” rating in a report on Friday, May 26th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $2.59.

Shares of BioLineRx (BLRX) traded up 3.51% on Monday, reaching $1.18. 1,123,323 shares of the company’s stock were exchanged. BioLineRx has a one year low of $0.79 and a one year high of $1.42. The firm’s market capitalization is $72.90 million. The firm has a 50 day moving average of $0.91 and a 200 day moving average of $0.96.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.05). On average, equities research analysts predict that BioLineRx will post ($0.25) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “BioLineRx Ltd. (BLRX) Given a $3.00 Price Target by Maxim Group Analysts” was reported by BBNS and is the sole property of of BBNS. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://baseballnewssource.com/markets/biolinerx-ltd-blrx-pt-set-at-3-00-by-maxim-group-updated-updated-updated/1196174.html.

Several large investors have recently made changes to their positions in the stock. Sabby Management LLC acquired a new position in shares of BioLineRx during the first quarter valued at approximately $3,018,000. KCG Holdings Inc. increased its position in shares of BioLineRx by 715.9% in the first quarter. KCG Holdings Inc. now owns 175,156 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 153,687 shares in the last quarter. Benchmark Capital Advisors increased its position in shares of BioLineRx by 227.3% in the first quarter. Benchmark Capital Advisors now owns 144,000 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 100,000 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of BioLineRx during the first quarter valued at approximately $126,000. Finally, Citadel Advisors LLC increased its position in shares of BioLineRx by 443.4% in the first quarter. Citadel Advisors LLC now owns 105,986 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 86,481 shares in the last quarter. Institutional investors and hedge funds own 34.91% of the company’s stock.

About BioLineRx

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.

Analyst Recommendations for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with our FREE daily email newsletter.

 


Latest News

Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns
Darren Daulton Former Catcher with Phillies Dies
Darren Daulton Former Catcher with Phillies Dies


Leave a Reply

 
© 2006-2017 BBNS.